有害事象と、治療歴のある非扁平上皮非小細胞肺がん(NSCLC)の成人参加者を対象に、単独療法として静脈内(IV)注入されたテリソツズマブ ベドチン(ABBV-399)がどのように体内に移行するかを評価する研究
治療歴のあるc-Met過剰発現、EGFR野生型、局所進行性/転移性非扁平上皮非小細胞肺がん患者を対象とした2つのテリソツズマブ ベドチンレジメンの第2相、非盲検、ランダム化、グローバル試験
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.
Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:ABBVIE CALL CENTER
- 電話番号:844-663-3742
- メール:abbvieclinicaltrials@abbvie.com
研究場所
-
-
Arizona
-
Chandler、Arizona、アメリカ、85224
- 募集
- Ironwood Cancer and Research Center /ID# 276370
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72205
- 募集
- University of Arkansas for Medical Sciences /ID# 272923
-
-
California
-
Los Angeles、California、アメリカ、90067
- 募集
- Valkyrie Clinical Trials /ID# 271322
-
Los Angeles、California、アメリカ、90025
- 募集
- Start Los Angeles /ID# 284999
-
Oxnard、California、アメリカ、93030
- 募集
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06510
- 完了
- Yale New Haven Hospital /ID# 271584
-
-
Florida
-
Jacksonville、Florida、アメリカ、32256
- 募集
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899
-
Ocala、Florida、アメリカ、34474
- 募集
- Ocala Oncology Center /ID# 273697
-
Pembroke Pines、Florida、アメリカ、33028
- 募集
- Memorial Hospital West /ID# 270313
-
St. Petersburg、Florida、アメリカ、33701-4732
- 募集
- Comprehensive Hematology Oncology /ID# 270422
-
St. Petersburg、Florida、アメリカ、33705
- 募集
- Florida Cancer Specialists - North /ID# 271995
-
West Palm Beach、Florida、アメリカ、33401
- 募集
- Florida Cancer Specialists - East /ID# 271993
-
-
Georgia
-
Athens、Georgia、アメリカ、30607
- 募集
- University Cancer and Blood Center /ID# 270969
-
Marietta、Georgia、アメリカ、30060
- 募集
- Northwest Georgia Oncology Centers /ID# 275374
-
Savannah、Georgia、アメリカ、31404
- 完了
- Memorial University Medical Center /ID# 272467
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96819
- 募集
- Kaiser Permanente Moanalua Medical Center /ID# 272916
-
-
Illinois
-
Chicago、Illinois、アメリカ、60607
- 募集
- University of Illinois Hospital and Health Sciences System /ID# 275345
-
Niles、Illinois、アメリカ、60714
- 募集
- Illinois Cancer Specialists /ID# 274678
-
Peoria、Illinois、アメリカ、61637-0001
- 募集
- OSF St. Francis Medical Center /ID# 281591
-
Springfield、Illinois、アメリカ、62702
- 募集
- Springfield Clinic - First /ID# 272576
-
-
Nebraska
-
Lincoln、Nebraska、アメリカ、68506
- 募集
- Nebraska Hematology-Oncology /ID# 272970
-
Omaha、Nebraska、アメリカ、68130
- 募集
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527
-
-
Nevada
-
Reno、Nevada、アメリカ、89502
- 募集
- Renown Regional Medical Center /ID# 273535
-
-
New Jersey
-
East Brunswick、New Jersey、アメリカ、08816-4096
- 募集
- Astera Cancer Care /ID# 272359
-
Teaneck、New Jersey、アメリカ、07666
- 募集
- Regional Cancer Care Associates /ID# 270783
-
-
New York
-
The Bronx、New York、アメリカ、10461
- 募集
- Montefiore Medical Center - Einstein Campus /ID# 277169
-
Westbury、New York、アメリカ、11590
- 募集
- Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455
-
-
North Carolina
-
Pinehurst、North Carolina、アメリカ、28374
- 募集
- FirstHealth of the Carolinas- Speciality Center /ID# 272924
-
-
Ohio
-
Perrysburg、Ohio、アメリカ、43551
- 募集
- Mercy Health - Perrysburg Cancer Center /ID# 270536
-
Zanesville、Ohio、アメリカ、43701
- 募集
- Genesis Healthcare System /ID# 273361
-
-
Pennsylvania
-
Sayre、Pennsylvania、アメリカ、18840
- 募集
- Guthrie Robert Packer Hospital /ID# 270316
-
York、Pennsylvania、アメリカ、17403
- 募集
- Cancer Care Associates Of York /ID# 270971
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- 募集
- Medical University of South Carolina /ID# 273272
-
Greenville、South Carolina、アメリカ、29607
- 募集
- Saint Francis Cancer Center - Greenville /ID# 276368
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- 募集
- SCRI Oncology Partners /ID# 270162
-
-
Texas
-
Dallas、Texas、アメリカ、75246
- 募集
- Texas Oncology - Dallas - Worth Street /ID# 278947
-
Tyler、Texas、アメリカ、75702
- 募集
- Texas Oncology - Northeast Texas /ID# 272000
-
-
Utah
-
Ogden、Utah、アメリカ、84405
- 募集
- Community Cancer Trials Of Utah /ID# 276598
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 募集
- Virginia Cancer Specialists - Fairfax /ID# 272004
-
-
Washington
-
Spokane、Washington、アメリカ、99208
- 募集
- Medical Oncology Associates - Spokane /ID# 277172
-
Tacoma、Washington、アメリカ、98405
- 募集
- Northwest Medical Specialties Tacoma /ID# 270534
-
-
-
-
-
Haifa、イスラエル、3109601
- 募集
- Rambam Health Care Campus- Haifa /ID# 270078
-
Jerusalem、イスラエル、9103102
- 完了
- Shaare Zedek Medical Center /ID# 270095
-
-
Central District
-
Kefar Sava、Central District、イスラエル、4428164
- 募集
- Meir Medical Center /ID# 270071
-
Petah Tikva、Central District、イスラエル、4941492
- 募集
- Rabin Medical Center. /ID# 270087
-
-
Tel Aviv
-
Ramat Gan、Tel Aviv、イスラエル、5265601
- 募集
- The Chaim Sheba Medical Center /ID# 270068
-
-
-
-
Central Singapore
-
Singapore、Central Singapore、シンガポール、169611
- 募集
- National Cancer Centre Singapore /ID# 271499
-
Singapore、Central Singapore、シンガポール、119074
- 募集
- National University Hospital /ID# 271700
-
-
-
-
Beograd
-
Belgrade、Beograd、セルビア、11000
- 募集
- Institute for Oncology and Radiology of Serbia /ID# 270561
-
Belgrade、Beograd、セルビア、11080
- 募集
- Clinical Hospital Center - Bezanijska Kosa /ID# 270558
-
Belgrade、Beograd、セルビア、11000
- 募集
- University Clinical Center Serbia /ID# 270808
-
Belgrade、Beograd、セルビア、11000
- 募集
- Military Medical Academy /ID# 279873
-
-
Nisavski Okrug
-
Niš、Nisavski Okrug、セルビア、18300
- 募集
- University Clinical Center Nis /ID# 270557
-
-
Sremski Okrug
-
Kamenitz、Sremski Okrug、セルビア、21208
- 募集
- Institute For Pulmonary Diseases Of Vojvodina /ID# 270559
-
-
Sumadijski Okrug
-
Kragujevac、Sumadijski Okrug、セルビア、34000
- 募集
- University Clinical Center Kragujevac /ID# 275773
-
-
-
-
-
São Paulo、ブラジル、01323-020
- 募集
- Hospital Alemao Oswaldo Cruz - Sao Paulo /ID# 272512
-
-
Ceará
-
Fortaleza、Ceará、ブラジル、60810-180
- 募集
- Suporte Nutricional e Quimioterapia LTDA - PRONUTRIR /ID# 273203
-
-
Paraná
-
Curitiba、Paraná、ブラジル、80510-130
- 募集
- Ictrials Pesquisa E Desenvolvimento /ID# 276681
-
-
Pará
-
Belém、Pará、ブラジル、66063-495
- 募集
- Cto - Centro De Tratamento Oncologico /ID# 276699
-
-
Pernambuco
-
Recife、Pernambuco、ブラジル、50040-000
- 募集
- Hospital De Cancer De Pernambuco /ID# 276104
-
-
Rio Grande do Norte
-
Natal、Rio Grande do Norte、ブラジル、59075-740
- 募集
- Liga Norte Riograndense Contra O Cancer /ID# 273183
-
-
Rio Grande do Sul
-
Ijuí、Rio Grande do Sul、ブラジル、98700-000
- 募集
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 272513
-
-
Santa Catarina
-
Florianópolis、Santa Catarina、ブラジル、88020-210
- 募集
- Cepen - Centro De Pesquisa E Ensino Em Oncologia De Santa Catarina /ID# 273204
-
-
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、101149
- 募集
- Beijing Chest Tumor Hospital /ID# 271935
-
-
Fujian
-
Fuzhou、Fujian、中国、350014
- 募集
- Fujian Province Cancer Hospital /ID# 276178
-
-
Guangxi
-
Nanning、Guangxi、中国、530021
- 募集
- Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国、150081
- 募集
- Harbin Medical University Cancer Hospital /ID# 271665
-
-
Henan
-
Zhengzhou、Henan、中国、450008
- 募集
- Henan Cancer Hospital /ID# 271927
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- 募集
- Union Hospital - Tongji Medical College /ID# 271668
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330006
- 募集
- The First Affiliated Hospital of Nanchang University /ID# 271666
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710061
- 募集
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928
-
-
Shandong
-
Linyi、Shandong、中国、276001
- 募集
- LinYi Cancer Hospital /ID# 272068
-
-
Xinjiang
-
Ürümqi、Xinjiang、中国、830011
- 募集
- Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933
-
-
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、466-8560
- 募集
- Nagoya University Hospital /ID# 277010
-
-
Chiba
-
Kashiwa-shi、Chiba、日本、277-8577
- 募集
- National Cancer Center Hospital East /ID# 277056
-
-
Hokkaido
-
Sapporo、Hokkaido、日本、060-8648
- 募集
- Hokkaido University Hospital /ID# 277014
-
-
Hyōgo
-
Kobe、Hyōgo、日本、650-0046
- 募集
- Kobe Minimally Invasive Cancer Center /ID# 277469
-
-
Kanagawa
-
Sagamihara-shi、Kanagawa、日本、252-0375
- 募集
- Kitasato University Hospital /ID# 277012
-
-
Miyagi
-
Sendai、Miyagi、日本、981-0914
- 募集
- Sendai Kousei Hospital /ID# 277023
-
-
Miyazaki
-
Miyazaki、Miyazaki、日本、889-1692
- 募集
- University of Miyazaki Hospital /ID# 277020
-
-
Okayama-ken
-
Kurashiki-shi、Okayama-ken、日本、710-8602
- 募集
- Kurashiki Central Hospital /ID# 276995
-
-
Shizuoka
-
Fujieda、Shizuoka、日本、426-0077
- 募集
- Fujieda Municipal General Hospital /ID# 277025
-
-
Wakayama
-
Wakayama、Wakayama、日本、641-8510
- 募集
- Wakayama Medical University Hospital /ID# 276997
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Projected life expectancy of at least 12 weeks.
- Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as >= 25% tumor cells with 3+ staining (high [>= 50% 3+]; intermediate [>= 25% - < 50%]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory
- Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.
- Must have a known epidermal growth factor receptor (EGFR) activating mutation status.
- Actionable alterations in genes other than EGFR are permitted.
- Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
- Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.
- Must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, as stated in the protocol.
Exclusion Criteria:
- Adenosquamous or neuroendocrine histology, or sarcomatoid features.
- EGFR activating mutations (e.g., EGFR Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).
- Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.
- Received prior docetaxel therapy.
- Metastases to the central nervous system (CNS). Participants with CNS metastases are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.
- History of other malignancies except those stated in the protocol.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.
- Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
- Major surgery within 21 days prior to randomization.
- Clinically significant condition(s) including but not limited to those listed in the protocol.
- Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.
- Grade >= 2 edema or lymphedema.
- Grade >= 2 ascites or pleural effusion.
- Grade >= 2 neuropathy.
- Active uncontrolled bacterial or viral infection.
- Active corneal disorder.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Telisotuzumab Vedotin Dose A
Participants will receive telisotuzumab vedotin dose A, as part of the 3 year study duration. |
Intravenous (IV) Infusion
他の名前:
|
|
実験的:Telisotuzumab Vedotin Dose B
Participants will receive telisotuzumab vedotin dose B, as part of the 3 year study duration. |
Intravenous (IV) Infusion
他の名前:
|
|
実験的:Telisotuzumab Vedotin Dose C
Participants will receive telisotuzumab vedotin dose C, as part of the 3 year study duration. |
Intravenous (IV) Infusion
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
時間枠:Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
時間枠:Up to Approximately 3 Years
|
ILD is defined by ILD standardized MedDRA query (SMQ) (broad) per investigator and determined per adjudication (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
時間枠:Up to Approximately 3 Years
|
Peripheral neuropathy is defined by peripheral neuropathy SMQ (narrow) (any-grade and Grade >= 2) |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
時間枠:Up to Approximately 3 Years
|
Treatment-emergent ocular surface disorders defined by corneal epitheliopathy company MedDRA query (CMQ) (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
時間枠:Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Grade 5 Treatment-Emergent AEs
時間枠:Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Objective Response (OR) by Blinded Independent Central Review (BICR)
時間枠:Up to Approximately 3 Years
|
OR will be defined as achieving confirmed complete response (CR) or confirmed partial response (PR) based on response evaluation criteria in solid tumors (RECIST), version 1.1. |
Up to Approximately 3 Years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Concentrations of Telisotuzumab Vedotin Conjugate in Serum
時間枠:Up to 26 Weeks
|
Concentrations of telisotuzumab vedotin conjugate in serum. |
Up to 26 Weeks
|
|
Concentrations of Monomethylauristatin E (MMAE) Payload in Plasma
時間枠:Up to 26 Weeks
|
Concentrations of MMAE payload in plasma. |
Up to 26 Weeks
|
|
Percentage of Participants with Antidrug Antibodies (ADAs) of Telisotuzumab Vedotin
時間枠:Up to 26 Weeks
|
Percentage of participants with ADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Percentage of Participants with Neutralizing Antidrug Antibodies (nADAs) of Telisotuzumab Vedotin
時間枠:Up to 26 Weeks
|
Percentage of participants with nADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
時間枠:Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present). |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G)
時間枠:Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The GP5 item ("I am bothered by side effects of treatment") of FACT-G is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on participants. |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Duration of Response (DoR) by BICR
時間枠:Up to Approximately 3 Years
|
DoR is defined for confirmed responders as the time from the participants' initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Progression-Free Survival (PFS) by BICR
時間枠:Up to Approximately 3 Years
|
PFS will be defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Overall Survival (OS)
時間枠:Up to Approximately 3 Years
|
OS will be defined as the time from randomization to death from any cause. |
Up to Approximately 3 Years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:ABBVIE INC.、AbbVie
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- M25-274
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 共有時間枠
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD 共有アクセス基準
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。